Revoking the Seize Order: Preventing Spontaneous Seizures With AAV in a CLN2 Mouse Model

Sudden unexpected death in epilepsy

(2023) Gordon F. Buchanan et al.   CURRENT OPINION IN NEUROLOGY

Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy

(2023) Arun Srivastava   Molecular Therapy-Nucleic Acids

Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis

(2022) Konrad Kaminiów et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Characterization of AAV-mediated dorsal root ganglionopathy

(2022) Nicholas Buss et al.   Molecular Therapy-Methods & Clinical Development

Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy

(2020) Nicola Specchio et al.   Therapeutics and Clinical Risk Management

AAV Vectors: Are They Safe?

(2020) Arun Srivastava   HUMAN GENE THERAPY

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

(2020) Zhou Han et al.   Science Translational Medicine

Scurrying to Understand Sudden Expected Death in Epilepsy: Insights From Animal Models

(2019) Rui Li et al.   Epilepsy Currents